drugset / Trial / NCT00334295
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the efficacy of a monthly administration of Fulvestrant in patients with recurrent or metastatic endometrial carcinoma by assessment of the clinical tumour response after 3 injections.
Timeline
- Start
- 2002-12
- Primary completion
- 2011-01
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | 250 mg | Intramuscular |